Schonfeld Strategic Advisors LLC Avrobio, Inc. Transaction History

Schonfeld Strategic Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.75 - $1.33 $7,500 - $13,300	-10,000 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.29 - $4.04 $12,900 - $40,400	10,000 New	10,000 $14,000
Q1 2021 May 17, 2021	SELL	$10.54 - $19.3 $220,475 - $403,717	-20,918 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$12.79 - $17.1 $11,536 - $15,424	902 Added 4.51%	20,918 $291,000
Q3 2020 Nov 16, 2020	SELL	$12.99 - $19.41 $96,606 - $144,352	-7,437 Reduced 27.09%	20,016 $0
Q2 2020 Aug 14, 2020	BUY	$12.19 - $22.96 $334,652 - $630,320	27,453 New	27,453 $479,000
Q4 2019 Feb 14, 2020	SELL	$13.05 - $21.88 $1.67 Million - $2.81 Million	-128,300 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$14.12 - $23.44 $1.81 Million - $3.01 Million	128,300 New	128,300 $1.81 Million

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.